Patents by Inventor Xuefan GAO

Xuefan GAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Interaction of Draxin and ?-netrins
    Patent number: 11505586
    Abstract: This invention relates to extracellular protein-protein interactions and their possible therapeutic uses. More particularly, this invention describes the interaction between Draxin, particularly fragments binding to ?-Netrins comprising SEQ ID NO.:1, 2 or 3, and variants thereof, with ?-Netrins, and the use of this interaction to disrupt ?-Netrin/Netrin receptor interactions. The invention also relates to diagnostic and/or therapeutic uses of Draxin or fragments or variants thereof, as well as to an antibody against Draxin inhibiting binding of Draxin to ?-Netrins. Further, the invention relates to fragments of ?-Netrins, in particular Draxin-binding Netrin1-fragments comprising SEQ ID NO.: 51 and variants thereof, as well as to an antibody against ?-Netrins inhibiting binding of ?-Netrins to Netrin receptors.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: November 22, 2022
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Christian Söllner, Xuefan Gao, Christiane Nüsslein-Volhard
  • INTERACTION OF DRAXIN AND Y-NETRINS
    Publication number: 20200040047
    Abstract: This invention relates to extracellular protein-protein interactions and their possible therapeutic uses. More particularly, this invention describes the interaction between Draxin, particularly fragments binding to ?-Netrins comprising SEQ ID NO.:1, 2 or 3, and variants thereof, with ?-Netrins, and the use of this interaction to disrupt ?-Netrin/Netrin receptor interactions. The invention also relates to diagnostic and/or therapeutic uses of Draxin or fragments or variants thereof, as well as to an antibody against Draxin inhibiting binding of Draxin to ?-Netrins. Further, the invention relates to fragments of ?-Netrins, in particular Draxin-binding Netrin1-fragments comprising SEQ ID NO.: 51 and variants thereof, as well as to an antibody against ?-Netrins inhibiting binding of ?-Netrins to Netrin receptors.
    Type: Application
    Filed: August 28, 2019
    Publication date: February 6, 2020
    Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Christian SÖLLNER, Xuefan GAO, Christiane NÜSSLEIN-VOLHARD
  • Interaction of draxin and ?-netrins
    Patent number: 10435442
    Abstract: This invention relates to extracellular protein-protein interactions and their possible therapeutic uses. More particularly, this invention describes the interaction between Draxin, particularly fragments binding to ?-Netrins comprising SEQ ID NO.: 1, 2 or 3, and variants thereof, with ?-Netrins, and the use of this interaction to disrupt ?-Netrin/Netrin receptor interactions. The invention also relates to diagnostic and/or therapeutic uses of Draxin or fragments or variants thereof, as well as to an antibody against Draxin inhibiting binding of Draxin to ?-Netrins. Further, the invention relates to fragments of ?-Netrins, in particular Draxin-binding Netrin1-fragments comprising SEQ ID NO.: 51 and variants thereof, as well as to an antibody against ?-Netrins inhibiting binding of ?-Netrins to Netrin receptors.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: October 8, 2019
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Christian Söllner, Xuefan Gao, Christiane Nüsslein-Volhard
  • INTERACTION OF DRAXIN AND Y-NETRINS
    Publication number: 20160347802
    Abstract: This invention relates to extracellular protein-protein interactions and their possible therapeutic uses. More particularly, this invention describes the interaction between Draxin, particularly fragments binding to ?-Netrins comprising SEQ ID NO.: 1, 2 or 3, and variants thereof, with ?-Netrins, and the use of this interaction to disrupt ?-Netrin/Netrin receptor interactions. The invention also relates to diagnostic and/or therapeutic uses of Draxin or fragments or variants thereof, as well as to an antibody against Draxin inhibiting binding of Draxin to ?-Netrins. Further, the invention relates to fragments of ?-Netrins, in particular Draxin-binding Netrin1-fragments comprising SEQ ID NO.: 51 and variants thereof, as well as to an antibody against ?-Netrins inhibiting binding of ?-Netrins to Netrin receptors.
    Type: Application
    Filed: January 21, 2015
    Publication date: December 1, 2016
    Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissens chaften e.V.
    Inventors: Christian SÖLLNET, Xuefan GAO, Christiane NÜSSLEIN-VOLHARD